AF
ACRS icon

Allworth Financial’s Aclaris Therapeutics ACRS Stock Holding History

Allworth Financial’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$184 Buy
+49
New +$165 ﹤0.01% 4937
2023
Q4 		– Sell
-38
Closed -$261 – 3451
2023
Q3 		$261 Buy
+38
New +$325 ﹤0.01% 3194

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Allworth Financial's ACRS Position: Q1 2026 in Review

Allworth Financial opened a new position in Aclaris Therapeutics (ACRS) in Q1 2026: 49 shares worth $184. The stake represents ﹤0.01% of the portfolio and ranks #4937 among its holdings. This is a return to the name: Allworth Financial previously reported a position in ACRS as recently as Q3 2023.

Allworth Financial first reported a position in ACRS in Q3 2023 and has held it in 2 quarters since. The position peaked at $261 in Q3 2023. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Allworth Financial held 49 shares of Aclaris Therapeutics worth $184 as of Q1 2026.
  • Aclaris Therapeutics was a new Allworth Financial position in Q1 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #4937 holding.
  • Allworth Financial first reported a position in Aclaris Therapeutics in Q3 2023 and has held it in 2 quarters since.
  • Allworth Financial's Aclaris Therapeutics position peaked at $261 in Q3 2023.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.